Peripheral neuropathies are characterized by nerves damage and axonal loss, and they
could be classified in hereditary or acquired forms. Acquired peripheral neuropathies are …

Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain are
challenging complications of cancer treatment. Many of the major classes of …

Lithium is an effective medication for the treatment of bipolar affective disorder.
Accumulating evidence suggests that inflammation plays a role in the pathogenesis of …

The ceramide-sphingosine 1-phosphate (S1P) rheostat is important in regulating cell fate.
Several chemotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic …

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of chemotherapics
such as taxanes, vinca alkaloids, and platinum compounds. In recent years, several reports …

Many commonly used chemotherapeutics including oxaliplatin are associated with the
development of a painful chemotherapy-induced peripheral neuropathy (CIPN). This dose …

A 3 AR agonists prevent paclitaxel-induced neuropathic pain via modulating spinal redox-
dependent signaling pathways (restoring glutamatergic homeostasis, attenuating …

Abstract Development of chemotherapy-induced neuropathic pain (CINP) compromises the
use of chemotherapy and greatly impacts thousands of lives. Unfortunately, there are no …

Central neuropathic pain is caused by a disease or lesion of the brain or spinal cord. It is
difficult to predict which patients will develop central pain syndromes after a central nervous …

Patients receiving paclitaxel for cancer treatment often develop an acute pain syndrome
(paclitaxel‐associated acute pain syndrome, P‐APS), which occurs immediately after …